Unacceptable Principal Diagnosis Codes
ICD-10-CM codes identified as unacceptable when used as principal diagnosis by MCE edit logic.
Source: Definitions of Medicare Code Edits v44.0, edit 9.
Advertisements
Codes on this list
2,666 codes, page 11 of 27.
- T44.8X5DAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
- T44.8X5SAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
- T44.8X6AUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
- T44.8X6DUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
- T44.8X6SUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela
- T44.905AAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
- T44.905DAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
- T44.905SAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
- T44.906AUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
- T44.906DUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
- T44.906SUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela
- T44.995AAdverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
- T44.995DAdverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
- T44.995SAdverse effect of other drug primarily affecting the autonomic nervous system, sequela
- T44.996AUnderdosing of other drug primarily affecting the autonomic nervous system, initial encounter
- T44.996DUnderdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter
- T44.996SUnderdosing of other drug primarily affecting the autonomic nervous system, sequela
- T45.0X5AAdverse effect of antiallergic and antiemetic drugs, initial encounter
- T45.0X5DAdverse effect of antiallergic and antiemetic drugs, subsequent encounter
- T45.0X5SAdverse effect of antiallergic and antiemetic drugs, sequela
- T45.0X6AUnderdosing of antiallergic and antiemetic drugs, initial encounter
- T45.0X6DUnderdosing of antiallergic and antiemetic drugs, subsequent encounter
- T45.0X6SUnderdosing of antiallergic and antiemetic drugs, sequela
- T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
- T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
- T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
- T45.1X6AUnderdosing of antineoplastic and immunosuppressive drugs, initial encounter
- T45.1X6DUnderdosing of antineoplastic and immunosuppressive drugs, subsequent encounter
- T45.1X6SUnderdosing of antineoplastic and immunosuppressive drugs, sequela
- T45.2X5AAdverse effect of vitamins, initial encounter
- T45.2X5DAdverse effect of vitamins, subsequent encounter
- T45.2X5SAdverse effect of vitamins, sequela
- T45.2X6AUnderdosing of vitamins, initial encounter
- T45.2X6DUnderdosing of vitamins, subsequent encounter
- T45.2X6SUnderdosing of vitamins, sequela
- T45.3X5AAdverse effect of enzymes, initial encounter
- T45.3X5DAdverse effect of enzymes, subsequent encounter
- T45.3X5SAdverse effect of enzymes, sequela
- T45.3X6AUnderdosing of enzymes, initial encounter
- T45.3X6DUnderdosing of enzymes, subsequent encounter
- T45.3X6SUnderdosing of enzymes, sequela
- T45.4X5AAdverse effect of iron and its compounds, initial encounter
- T45.4X5DAdverse effect of iron and its compounds, subsequent encounter
- T45.4X5SAdverse effect of iron and its compounds, sequela
- T45.4X6AUnderdosing of iron and its compounds, initial encounter
- T45.4X6DUnderdosing of iron and its compounds, subsequent encounter
- T45.4X6SUnderdosing of iron and its compounds, sequela
- T45.515AAdverse effect of anticoagulants, initial encounter
- T45.515DAdverse effect of anticoagulants, subsequent encounter
- T45.515SAdverse effect of anticoagulants, sequela
- T45.516AUnderdosing of anticoagulants, initial encounter
- T45.516DUnderdosing of anticoagulants, subsequent encounter
- T45.516SUnderdosing of anticoagulants, sequela
- T45.525AAdverse effect of antithrombotic drugs, initial encounter
- T45.525DAdverse effect of antithrombotic drugs, subsequent encounter
- T45.525SAdverse effect of antithrombotic drugs, sequela
- T45.526AUnderdosing of antithrombotic drugs, initial encounter
- T45.526DUnderdosing of antithrombotic drugs, subsequent encounter
- T45.526SUnderdosing of antithrombotic drugs, sequela
- T45.605AAdverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
- T45.605DAdverse effect of unspecified fibrinolysis-affecting drugs, subsequent encounter
- T45.605SAdverse effect of unspecified fibrinolysis-affecting drugs, sequela
- T45.606AUnderdosing of unspecified fibrinolysis-affecting drugs, initial encounter
- T45.606DUnderdosing of unspecified fibrinolysis-affecting drugs, subsequent encounter
- T45.606SUnderdosing of unspecified fibrinolysis-affecting drugs, sequela
- T45.615AAdverse effect of thrombolytic drugs, initial encounter
- T45.615DAdverse effect of thrombolytic drugs, subsequent encounter
- T45.615SAdverse effect of thrombolytic drugs, sequela
- T45.616AUnderdosing of thrombolytic drugs, initial encounter
- T45.616DUnderdosing of thrombolytic drugs, subsequent encounter
- T45.616SUnderdosing of thrombolytic drugs, sequela
- T45.625AAdverse effect of hemostatic drug, initial encounter
- T45.625DAdverse effect of hemostatic drug, subsequent encounter
- T45.625SAdverse effect of hemostatic drug, sequela
- T45.626AUnderdosing of hemostatic drugs, initial encounter
- T45.626DUnderdosing of hemostatic drugs, subsequent encounter
- T45.626SUnderdosing of hemostatic drugs, sequela
- T45.695AAdverse effect of other fibrinolysis-affecting drugs, initial encounter
- T45.695DAdverse effect of other fibrinolysis-affecting drugs, subsequent encounter
- T45.695SAdverse effect of other fibrinolysis-affecting drugs, sequela
- T45.696AUnderdosing of other fibrinolysis-affecting drugs, initial encounter
- T45.696DUnderdosing of other fibrinolysis-affecting drugs, subsequent encounter
- T45.696SUnderdosing of other fibrinolysis-affecting drugs, sequela
- T45.7X5AAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
- T45.7X5DAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter
- T45.7X5SAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
- T45.7X6AUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, initial encounter
- T45.7X6DUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, subsequent encounter
- T45.7X6SUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, sequela
- T45.8X5AAdverse effect of other primarily systemic and hematological agents, initial encounter
- T45.8X5DAdverse effect of other primarily systemic and hematological agents, subsequent encounter
- T45.8X5SAdverse effect of other primarily systemic and hematological agents, sequela
- T45.8X6AUnderdosing of other primarily systemic and hematological agents, initial encounter
- T45.8X6DUnderdosing of other primarily systemic and hematological agents, subsequent encounter
- T45.8X6SUnderdosing of other primarily systemic and hematological agents, sequela
- T45.95XAAdverse effect of unspecified primarily systemic and hematological agent, initial encounter
- T45.95XDAdverse effect of unspecified primarily systemic and hematological agent, subsequent encounter
- T45.95XSAdverse effect of unspecified primarily systemic and hematological agent, sequela
- T45.96XAUnderdosing of unspecified primarily systemic and hematological agent, initial encounter
- T45.96XDUnderdosing of unspecified primarily systemic and hematological agent, subsequent encounter